Skip to main content

Table 4 Relative risk of second primary cancer by type of first primary cancer and time period of first diagnosis, Queensland, 1982-2006

From: The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study

 

Time period of first diagnosis

 

1982-1986

1987-1991

1992-1996

1997-2001

First primary cancer

Obs.

SIR

(95% CI)

Obs.

SIR

(95% CI)

Obs.

SIR

(95% CI)

Obs.

SIR

(95% CI)

   Head and neck

165

1.92

(1.64-2.23)

204

1.88

(1.63-2.16)

271

1.98

(1.75-2.23)

255

1.93

(1.70-2.18)

   Oesophagus

8

1.53

(0.66-3.02)

10

0.90

(0.43-1.66)

23

1.60

(1.01-2.39)

23

1.19

(0.76-1.79)

   Stomach

18

0.75

(0.44-1.18)

27

1.02

(0.67-1.49)

30

0.91

(0.62-1.31)

36

1.09

(0.76-1.51)

   Colorectal

198

0.89

(0.77-1.02)

273

0.95

(0.84-1.07)

411

1.07

(0.97-1.18)

559

1.20

(1.11-1.31)

   Pancreas

7

1.20

(0.48-2.47)

5

0.61

(0.20-1.42)

10

0.98

(0.47-1.81)

12

0.83

(0.43-1.45)

   Lung

71

1.06

(0.83-1.34)

93

1.14

(0.92-1.40)

147

1.61

(1.36-1.89)

148

1.30

(1.10-1.53)

   Melanoma

311

1.81

(1.62-2.02)

471

1.89

(1.72-2.07)

639

2.04

(1.88-2.20)

835

2.02

(1.89-2.16)

   Breast - female

152

0.97

(0.82-1.14)

199

0.94

(0.81-1.08)

359

1.32

(1.19-1.47)

504

1.37

(1.25-1.50)

   Cervix

24

1.29

(0.83-1.92)

38

1.88

(1.33-2.58)

34

1.64

(1.14-2.29)

26

1.55

(1.01-2.27)

   Uterus

30

1.14

(0.77-1.63)

35

1.18

(0.82-1.64)

35

0.87

(0.60-1.21)

63

1.30

(0.99-1.66)

   Ovary

16

1.36

(0.78-2.20)

10

0.64

(0.31-1.18)

26

1.35

(0.88-1.98)

24

1.02

(0.66-1.52)

   Prostate

163

0.64

(0.54-0.74)

291

0.76

(0.68-0.85)

603

0.84

(0.77-0.91)

655

0.95

(0.88-1.02)

   Kidney

44

1.48

(1.08-1.99)

73

1.79

(1.40-2.25)

92

1.53

(1.24-1.88)

160

2.04

(1.74-2.38)

   Bladder

137

1.46

(1.22-1.72)

189

1.78

(1.53-2.05)

238

1.84

(1.61-2.09)

353

2.22

(2.00-2.47)

   Brain & CNS

--

--

5

1.00

(0.33-2.34)

--

--

9

1.10

(0.50-2.09)

   Thyroid

9

1.25

(0.57-2.38)

12

1.25

(0.64-2.18)

29

1.64

(1.10-2.36)

46

1.67

(1.22-2.23)

   Non-Hodgkin lymphoma

42

1.09

(0.79-1.48)

62

1.15

(0.88-1.48)

88

1.25

(1.00-1.54)

144

1.49

(1.25-1.75)

   Lymphoid leukaemia

24

1.00

(0.64-1.48)

33

1.25

(0.86-1.75)

63

1.68

(1.29-2.15)

88

1.71

(1.37-2.10)

   Myeloid leukaemia

13

1.23

(0.66-2.11)

11

0.91

(0.45-1.62)

26

1.52

(0.99-2.22)

34

2.05

(1.42-2.86)

   Myeloma/PCT

21

1.37

(0.85-2.10)

7

0.46

(0.19-0.95)

19

0.83

(0.50-1.29)

39

1.05

(0.75-1.44)

   Other

79

0.94

(0.74-1.17)

136

1.22

(1.03-1.45)

241

1.43

(1.26-1.62)

318

1.43

(1.28-1.60)

   All cancers combined

1,534

1.14

(1.08-1.20)

2,184

1.22

(1.17-1.28)

3,386

1.36

(1.31-1.41)

4,331

1.46

(1.41-1.50)

  1. Obs. = Observed number of second primary cancers; SIR = standardised incidence ratio; CI = confidence interval; CNS = central nervous system; PCT = plasma cell tumours. Analysis by period of first diagnosis was restricted to five years of follow-up to allow more consistent comparisons across time. SIRs shown in normal bold font indicate significantly increased risk; SIRs shown in bold italics indicate significantly decreased risk. Estimates are not shown for Brain & CNS for the periods 1982-1986 and 1992-1996 due to observed cell counts of less than 5.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us